DK3004896T3 - Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf - Google Patents

Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf Download PDF

Info

Publication number
DK3004896T3
DK3004896T3 DK14735056.5T DK14735056T DK3004896T3 DK 3004896 T3 DK3004896 T3 DK 3004896T3 DK 14735056 T DK14735056 T DK 14735056T DK 3004896 T3 DK3004896 T3 DK 3004896T3
Authority
DK
Denmark
Prior art keywords
surfactures
marker
applications
under acid
acid sphingomyelinase
Prior art date
Application number
DK14735056.5T
Other languages
Danish (da)
English (en)
Inventor
Wei-Lien Chuang
Gerald F Cox
X Kate Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK3004896T3 publication Critical patent/DK3004896T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012Sphingomyelin phosphodiesterase (3.1.4.12)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08Sphingolipids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
DK14735056.5T 2013-06-07 2014-06-06 Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf DK3004896T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
PCT/US2014/041405 WO2014197859A1 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Publications (1)

Publication Number Publication Date
DK3004896T3 true DK3004896T3 (da) 2020-01-06

Family

ID=51062988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14735056.5T DK3004896T3 (da) 2013-06-07 2014-06-06 Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf

Country Status (29)

Country Link
US (4) US10022428B2 (enExample)
EP (2) EP3584580A1 (enExample)
JP (4) JP6457501B2 (enExample)
KR (3) KR102292298B1 (enExample)
CN (2) CN115128287A (enExample)
AU (5) AU2014274670B2 (enExample)
CA (1) CA2914751C (enExample)
CL (1) CL2015003563A1 (enExample)
CR (1) CR20150638A (enExample)
DK (1) DK3004896T3 (enExample)
EA (1) EA035342B1 (enExample)
ES (1) ES2762608T3 (enExample)
HR (1) HRP20192246T1 (enExample)
HU (1) HUE047863T2 (enExample)
IL (3) IL284102B2 (enExample)
LT (1) LT3004896T (enExample)
MA (1) MA38638B1 (enExample)
MX (1) MX370570B (enExample)
MY (1) MY185990A (enExample)
NZ (1) NZ754328A (enExample)
PH (1) PH12015502687A1 (enExample)
PL (1) PL3004896T3 (enExample)
PT (1) PT3004896T (enExample)
RS (1) RS59677B1 (enExample)
SG (2) SG10201709925SA (enExample)
SI (1) SI3004896T1 (enExample)
UA (1) UA120591C2 (enExample)
WO (1) WO2014197859A1 (enExample)
ZA (1) ZA201508630B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
PL3004896T3 (pl) * 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病c型を予防または治療するための医薬組成物
SG11202001544VA (en) * 2017-08-24 2020-03-30 Sanofi Sa Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元lc-ms/msシステム
EP4562432A2 (en) * 2022-07-28 2025-06-04 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US5773278A (en) * 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) * 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
CA2634042A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd 3次元測位システム
JP6243846B2 (ja) * 2011-11-15 2017-12-06 セントジーン アーゲー ニーマン・ピック病の診断のための方法
WO2014183873A1 (en) * 2013-05-14 2014-11-20 Centogene Ag Method for the diagnosis of niemann-pick disease
PL3004896T3 (pl) * 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania

Also Published As

Publication number Publication date
BR112015030099A2 (pt) 2017-07-25
AU2014274670B2 (en) 2017-11-09
JP6457501B2 (ja) 2019-01-23
US20240398907A1 (en) 2024-12-05
AU2023201062A1 (en) 2023-03-23
EP3584580A1 (en) 2019-12-25
WO2014197859A1 (en) 2014-12-11
CR20150638A (es) 2016-02-08
KR20210031541A (ko) 2021-03-19
MX370570B (es) 2019-12-17
PH12015502687A1 (en) 2016-03-07
HRP20192246T1 (hr) 2020-03-06
IL284102B (en) 2022-12-01
JP7414750B2 (ja) 2024-01-16
EA201592265A1 (ru) 2016-04-29
KR102292298B1 (ko) 2021-08-24
SG10201709925SA (en) 2017-12-28
AU2014274670A1 (en) 2016-01-07
US10888607B2 (en) 2021-01-12
CL2015003563A1 (es) 2016-08-05
MA38638A1 (fr) 2017-02-28
AU2018200977A1 (en) 2018-03-01
KR20210104177A (ko) 2021-08-24
KR102434244B1 (ko) 2022-08-19
IL284102A (en) 2021-07-29
US11998592B2 (en) 2024-06-04
JP2016526050A (ja) 2016-09-01
US20180289778A1 (en) 2018-10-11
MA38638B1 (fr) 2018-03-30
IL298675B2 (en) 2025-12-01
PT3004896T (pt) 2019-12-23
NZ715001A (en) 2021-10-29
KR102228367B1 (ko) 2021-03-16
RS59677B1 (sr) 2020-01-31
EP3004896A1 (en) 2016-04-13
CN105474017A (zh) 2016-04-06
IL298675B1 (en) 2025-08-01
AU2023201062B2 (en) 2025-05-29
CA2914751C (en) 2023-10-03
AU2020257114B2 (en) 2023-03-16
AU2025220876A1 (en) 2025-09-11
PL3004896T3 (pl) 2020-04-30
IL284102B2 (en) 2023-04-01
AU2020257114A1 (en) 2020-11-19
US20160120958A1 (en) 2016-05-05
ZA201508630B (en) 2020-01-29
KR20160018651A (ko) 2016-02-17
HK1217534A1 (en) 2017-01-13
EP3004896B1 (en) 2019-09-18
MY185990A (en) 2021-06-14
JP2024038145A (ja) 2024-03-19
SG11201509622WA (en) 2015-12-30
ES2762608T3 (es) 2020-05-25
US20210162021A1 (en) 2021-06-03
JP2021075544A (ja) 2021-05-20
AU2018200977B2 (en) 2020-07-23
EA035342B1 (ru) 2020-05-29
MX2015016844A (es) 2016-04-04
US10022428B2 (en) 2018-07-17
JP6835806B2 (ja) 2021-02-24
UA120591C2 (uk) 2020-01-10
NZ754328A (en) 2021-12-24
HUE047863T2 (hu) 2020-05-28
IL242964B (en) 2021-07-29
IL298675A (en) 2023-01-01
CN115128287A (zh) 2022-09-30
LT3004896T (lt) 2020-01-10
JP2019089767A (ja) 2019-06-13
SI3004896T1 (sl) 2020-01-31
CA2914751A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3043784T3 (da) Arylethere og anvendelser deraf
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK3683235T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
EP2973234A4 (en) DENDRITICAL STRUCTURES AND LABELS
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
DK2999103T3 (da) Konverter og fremgangsmåde til styring deraf
DK3027209T3 (da) Anti-Activin A-antistoffer og anvendelser deraf
IL245036B (en) Pesticidal compositions and related methods
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
IL298675B2 (en) Marker for acid sphingomyelinase disorders and its uses
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
DK2947141T3 (da) Mikroorganismer der fremstiller docosahexaensyre og anvendelse deraf
DK3016547T3 (da) Dyrebarriere og fremgangsmåde
DK3060922T3 (da) Fremgangsmåde og anordning til proteinfremstilling
DK2994150T3 (da) Probiotika og fremgangsmåde til anvendelse
DK3083523T3 (da) Silicasammensætning og fremgangsmåde til fremstilling
DK3060225T3 (da) Leveringssystem og probiotisk sammensætning til dyr